Effect of fenofibrate in 1113 patients at lowdensity lipoprotein cholesterol goal but high triglyceride levels: Real-world results and factors associated with triglyceride reduction

Yeongmin Woo, Jeong Soo Shin, Chi Young Shim, Jung Sun Kim, Byeong Keuk Kim, Sungha Park, Hyuk Jae Chang, Geu Ru Hong, Young Guk Ko, Seok Min Kang, Donghoon Choi, Jong Won Ha, Myeong Ki Hong, Yangsoo Jang, Sang Hak Lee

Research output: Contribution to journalArticle

Abstract

Fibrates are used in patients with dyslipidemia and high cardiovascular risk. However, information regarding drug response to fibrate has been highly limited. We investigated treatment results and factors associated with triglyceride reduction after fenofibrate therapy using large-scale real-world data. Patients with one or more cardiovascular risk factors, at low-density lipoprotein-cholesterol goal but with triglyceride level 150 mg/dL, and undergoing treatment with fenofibrate 135±160 mg for the first time were included in this retrospective observational study. The outcome variable was the percentage changes of TG levels. The achievement rate of triglyceride <150 mg/dL was additionally analyzed. Factors associated with treatment results were also analyzed. Among 2546 patients who were initially screened, 1113 patients were enrolled (median age: 61 years; male: 71%). After median follow- up of 4 months, the median change in triglyceride was -60%, and 49% of the patients reached triglyceride <150 mg/dL. After adjusting for confounding variables, female sex, non-diabetic status, coronary artery disease, lower baseline triglyceride, and no statin use were identified to be independently associated with achievement of triglyceride <150 mg/dL. Among them, female sex, non-diabetic status, and coronary artery disease were also related to median or greater percentage reduction of triglyceride. In conclusion, only half of the study patients reached triglyceride levels <150 mg/dL after real-world fenofibrate therapy. This study indicates that more attention is needed on some subgroups to obtain optimal triglyceride levels when treating with fenofibrate.

Original languageEnglish
Article numbere0205006
JournalPloS one
Volume13
Issue number10
DOIs
Publication statusPublished - 2018 Oct

Fingerprint

Fenofibrate
lipoproteins
Triglycerides
triacylglycerols
cholesterol
Fibric Acids
Coronary Artery Disease
lipoprotein cholesterol
fenofibrate
Therapeutics
Hydroxymethylglutaryl-CoA Reductase Inhibitors
therapeutics
Confounding Factors (Epidemiology)
gender
hyperlipidemia
observational studies
Dyslipidemias
low density lipoprotein cholesterol
LDL Cholesterol
Observational Studies

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

@article{4fbeedbc629940efaaf6e7f2fb075fe6,
title = "Effect of fenofibrate in 1113 patients at lowdensity lipoprotein cholesterol goal but high triglyceride levels: Real-world results and factors associated with triglyceride reduction",
abstract = "Fibrates are used in patients with dyslipidemia and high cardiovascular risk. However, information regarding drug response to fibrate has been highly limited. We investigated treatment results and factors associated with triglyceride reduction after fenofibrate therapy using large-scale real-world data. Patients with one or more cardiovascular risk factors, at low-density lipoprotein-cholesterol goal but with triglyceride level 150 mg/dL, and undergoing treatment with fenofibrate 135±160 mg for the first time were included in this retrospective observational study. The outcome variable was the percentage changes of TG levels. The achievement rate of triglyceride <150 mg/dL was additionally analyzed. Factors associated with treatment results were also analyzed. Among 2546 patients who were initially screened, 1113 patients were enrolled (median age: 61 years; male: 71{\%}). After median follow- up of 4 months, the median change in triglyceride was -60{\%}, and 49{\%} of the patients reached triglyceride <150 mg/dL. After adjusting for confounding variables, female sex, non-diabetic status, coronary artery disease, lower baseline triglyceride, and no statin use were identified to be independently associated with achievement of triglyceride <150 mg/dL. Among them, female sex, non-diabetic status, and coronary artery disease were also related to median or greater percentage reduction of triglyceride. In conclusion, only half of the study patients reached triglyceride levels <150 mg/dL after real-world fenofibrate therapy. This study indicates that more attention is needed on some subgroups to obtain optimal triglyceride levels when treating with fenofibrate.",
author = "Yeongmin Woo and Shin, {Jeong Soo} and Shim, {Chi Young} and Kim, {Jung Sun} and Kim, {Byeong Keuk} and Sungha Park and Chang, {Hyuk Jae} and Hong, {Geu Ru} and Ko, {Young Guk} and Kang, {Seok Min} and Donghoon Choi and Ha, {Jong Won} and Hong, {Myeong Ki} and Yangsoo Jang and Lee, {Sang Hak}",
year = "2018",
month = "10",
doi = "10.1371/journal.pone.0205006",
language = "English",
volume = "13",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "10",

}

Effect of fenofibrate in 1113 patients at lowdensity lipoprotein cholesterol goal but high triglyceride levels : Real-world results and factors associated with triglyceride reduction. / Woo, Yeongmin; Shin, Jeong Soo; Shim, Chi Young; Kim, Jung Sun; Kim, Byeong Keuk; Park, Sungha; Chang, Hyuk Jae; Hong, Geu Ru; Ko, Young Guk; Kang, Seok Min; Choi, Donghoon; Ha, Jong Won; Hong, Myeong Ki; Jang, Yangsoo; Lee, Sang Hak.

In: PloS one, Vol. 13, No. 10, e0205006, 10.2018.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Effect of fenofibrate in 1113 patients at lowdensity lipoprotein cholesterol goal but high triglyceride levels

T2 - Real-world results and factors associated with triglyceride reduction

AU - Woo, Yeongmin

AU - Shin, Jeong Soo

AU - Shim, Chi Young

AU - Kim, Jung Sun

AU - Kim, Byeong Keuk

AU - Park, Sungha

AU - Chang, Hyuk Jae

AU - Hong, Geu Ru

AU - Ko, Young Guk

AU - Kang, Seok Min

AU - Choi, Donghoon

AU - Ha, Jong Won

AU - Hong, Myeong Ki

AU - Jang, Yangsoo

AU - Lee, Sang Hak

PY - 2018/10

Y1 - 2018/10

N2 - Fibrates are used in patients with dyslipidemia and high cardiovascular risk. However, information regarding drug response to fibrate has been highly limited. We investigated treatment results and factors associated with triglyceride reduction after fenofibrate therapy using large-scale real-world data. Patients with one or more cardiovascular risk factors, at low-density lipoprotein-cholesterol goal but with triglyceride level 150 mg/dL, and undergoing treatment with fenofibrate 135±160 mg for the first time were included in this retrospective observational study. The outcome variable was the percentage changes of TG levels. The achievement rate of triglyceride <150 mg/dL was additionally analyzed. Factors associated with treatment results were also analyzed. Among 2546 patients who were initially screened, 1113 patients were enrolled (median age: 61 years; male: 71%). After median follow- up of 4 months, the median change in triglyceride was -60%, and 49% of the patients reached triglyceride <150 mg/dL. After adjusting for confounding variables, female sex, non-diabetic status, coronary artery disease, lower baseline triglyceride, and no statin use were identified to be independently associated with achievement of triglyceride <150 mg/dL. Among them, female sex, non-diabetic status, and coronary artery disease were also related to median or greater percentage reduction of triglyceride. In conclusion, only half of the study patients reached triglyceride levels <150 mg/dL after real-world fenofibrate therapy. This study indicates that more attention is needed on some subgroups to obtain optimal triglyceride levels when treating with fenofibrate.

AB - Fibrates are used in patients with dyslipidemia and high cardiovascular risk. However, information regarding drug response to fibrate has been highly limited. We investigated treatment results and factors associated with triglyceride reduction after fenofibrate therapy using large-scale real-world data. Patients with one or more cardiovascular risk factors, at low-density lipoprotein-cholesterol goal but with triglyceride level 150 mg/dL, and undergoing treatment with fenofibrate 135±160 mg for the first time were included in this retrospective observational study. The outcome variable was the percentage changes of TG levels. The achievement rate of triglyceride <150 mg/dL was additionally analyzed. Factors associated with treatment results were also analyzed. Among 2546 patients who were initially screened, 1113 patients were enrolled (median age: 61 years; male: 71%). After median follow- up of 4 months, the median change in triglyceride was -60%, and 49% of the patients reached triglyceride <150 mg/dL. After adjusting for confounding variables, female sex, non-diabetic status, coronary artery disease, lower baseline triglyceride, and no statin use were identified to be independently associated with achievement of triglyceride <150 mg/dL. Among them, female sex, non-diabetic status, and coronary artery disease were also related to median or greater percentage reduction of triglyceride. In conclusion, only half of the study patients reached triglyceride levels <150 mg/dL after real-world fenofibrate therapy. This study indicates that more attention is needed on some subgroups to obtain optimal triglyceride levels when treating with fenofibrate.

UR - http://www.scopus.com/inward/record.url?scp=85054428457&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054428457&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0205006

DO - 10.1371/journal.pone.0205006

M3 - Article

C2 - 30286170

AN - SCOPUS:85054428457

VL - 13

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 10

M1 - e0205006

ER -